Search
Kairos Pharma Ltd
KAPAAdd to Watchlist
0.427USD
0.0000.00%
Market hours （ET）Quotes delayed by 15 min
9.15MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-23The current earnings forecast score of Kairos Pharma Ltd is 8.00, ranking 166 out of 389 in the Biotechnology & Medical Research industry. The average price target is 9.00, with a high of 12.00 and a low of 4.00.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
12.000
Target Price
+2684.22%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
561
Total
5
Median
6
Average
Company name
Ratings
Analysts
Kairos Pharma Ltd
KAPA
2
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
IQVIA Holdings Inc
IQV
26
CRISPR Therapeutics AG
CRSP
26
argenx SE
ARGX
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Kairos Pharma Ltd's price target?
Analysts forecast that Kairos Pharma Ltd's price target is USD 9.00, with the highest forecast at USD 12.00 and the lowest forecast at USD 4.00.
How have Kairos Pharma LtdKAPA's recent earnings per share performed?
The market expectation was USD -0.08, while Kairos Pharma LtdKAPA's earnings per share (EPS) for the previous quarter was USD -0.07. EPS for the next quarter is expected at USD -0.09.
What is the analyst rating for Kairos Pharma Ltd?
Based on the ratings of Kairos Pharma Ltd's stock from 2 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
